47. Buerger disease
7 clinical trials,   9 drugs   (DrugBank: 4 drugs),   4 drug target genes,   13 drug target pathways
Searched query = "Buerger disease", "Thromboangiitis obliterans"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03056742 (ClinicalTrials.gov) | February 20, 2017 | 23/1/2017 | A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease | A Single Arm, Open Label, Multicentric, Clinical Study Assessing the Efficacy and Safety of Stempeucel® (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells) in Patients With CLI Due to Buerger's Disease | Critical Limb Ischemia Due to Buerger's Disease | Biological: Stempeucel(R) | Stempeutics Research Pvt Ltd | NULL | Withdrawn | 18 Years | 65 Years | All | 0 | Phase 2 | India |